phenobarbital Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Phenobarbital, also known as phenobarbitone or phenobarb, sold under the brand name Luminal among others, is a medication of the barbiturate type. It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries. In the developed world, it is commonly used to treat seizures in young children, while other medications are generally used in older children and adults. In developed countries it is used for veterinary purposes. It may be used intravenously, injected into a muscle, or taken by mouth. The injectable form may be used to treat status epilepticus. Phenobarbital is occasionally used to treat trouble sleeping, anxiety, and drug withdrawal and to help with surgery. It usually begins working within five minutes when used intravenously and half an hour when administered by mouth. Its effects last for between four hours and two days.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0042 - $2.5930
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5-ethyl-5-phenyl-2,4,6(1h,3h,5h)-pyrimidinetrione | 5-ethyl-5-phenylbarbituric acid | 5-ethyl-5-phenylpyrimidine-2,4,6(1h,3h,5h)-trione | 5-ethyl-5-phenyl-pyrimidine-2,4,6-trione | 5-phenyl-5-ethylbarbituric acid | adonal | dormiral | eskabarb | gardenal sod | luminal | luminal sodium | neurobarb | noptil | phenaemal | phenemal | phenobarbital | phenobarbital sod | phenobarbital sodium | phenobarbitol | phenobarbitone | phenobarbituric acid | phenylaethylbarbitursaeure | phenylethylbarbiturate | phenylethylbarbituric acid | phenylethylbarbitursaeure | phenylethylmalonylurea | sedophen | sodium phenobarbital | solfoton | talpheno | versomnal

Organizations (53)

Research & Development (51)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (32)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (32)


 

Acute Kidney Injury (Phase 4)

Alcohol Withdrawal Delirium (Phase 4)

Analgesics, Opioid (Phase 3)

Anxiety Disorders (Phase 3)

Astrocytoma (Phase 1)

Dementia (Phase 3)

Depression (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 1)

Drug Resistant Epilepsy (Phase 4)

Epilepsy ()

Epilepsy, Benign Neonatal (Phase 3)

Glioblastoma (Phase 1)

Glioma (Phase 4)

Gliosarcoma (Phase 1)

Infant, Low Birth Weight (Phase 3)

Infant, Newborn (Phase 3)

Infant, Premature (Phase 3)

Infant, Small for Gestational Age (Phase 3)

Intestinal Neoplasms (Phase 1)

Intracranial Hemorrhages (Phase 3)

Lymphoma (Phase 1)

Neonatal Abstinence Syndrome (Phase 3)

Neoplasms (Phase 1)

Neutropenia (Phase 1)

Oligodendroglioma (Phase 1)

Pediatrics (Phase 3)

Pharmacokinetics (Phase 4)

Psychophysiologic Disorders (Phase 3)

Renal Insufficiency (Phase 4)

Schizophrenia (Phase 3)

Seizures (Phase 4)

Status Epilepticus (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 29
  • # of Trial Organizations: 51

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue